Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Panobinostat |
Synonyms | |
Therapy Description |
Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). Farydak (panobinostat) is FDA approved, in combination with Velcade (Bortezomib) and dexamethasone, for multiple myeloma (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Panobinostat | Farydak | LBH589 | HDAC Inhibitor 45 | Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). Farydak (panobinostat) is FDA approved, in combination with Velcade (Bortezomib) and dexamethasone, for multiple myeloma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 R132H | high grade glioma | decreased response | Panobinostat | Preclinical - Cell culture | Actionable | In a preclinical study, mouse glioma cells expressing IDH1 R132H were less sensitive to Farydak (panobinostat) compared to IDH1 wild-type cells in culture (PMID: 38334611). | 38334611 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01032148 | Phase I | Panobinostat | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT02032810 | Phase I | Panobinostat Ipilimumab | Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | Completed | USA | 0 |
NCT00946647 | Phase II | Panobinostat Azacitidine | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | Completed | USA | SWE | ITA | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | 2 |
NCT05725200 | Phase II | Dasatinib Palbociclib Gemcitabine Trastuzumab Cetuximab Pertuzumab Panobinostat Alectinib Venetoclax Larotrectinib Encorafenib Everolimus Idelalisib Crizotinib Pembrolizumab Methotrexate Talazoparib | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer (EVIDENT) | Recruiting | NOR | 0 |
NCT04804709 | Phase I | Panobinostat | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) | Active, not recruiting | USA | 0 |
NCT02717455 | Phase I | Panobinostat | Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma | Completed | USA | 0 |
NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Terminated | USA | 0 |
NCT04326764 | Phase III | Panobinostat | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | Terminated | NLD | DEU | 0 |
NCT02506959 | Phase II | Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma | Completed | USA | 0 |
NCT01321346 | Phase I | Cytarabine Panobinostat | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT02720510 | Phase II | Panobinostat Bortezomib + Dexamethasone + Lenalidomide | A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) | Terminated | USA | 0 |
NCT04897880 | Phase II | Panobinostat | A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT (NORTH) | Terminated | USA | NZL | AUS | 0 |
NCT01336842 | Phase I | Cisplatin Panobinostat Pemetrexed Disodium | Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | Completed | USA | 0 |
NCT01169636 | Phase Ib/II | Panobinostat Pegfilgrastim Carboplatin + Etoposide + Ifosfamide | Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | Completed | USA | 0 |
NCT02722941 | Phase II | Panobinostat | Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | Completed | USA | 0 |